Search Results

An older, white man smiles and is joined by his wife, who is also white, as he speaks to his doctor

People with CLL are living longer than ever before, and cures are on the horizon

People with the most common type of blood cancer, chronic lymphocytic leukemia (CLL), are living longer than ever before without their disease progressing. While cures for CLL patients are still rare, survival rates have improved steadily over the last 50 years, with nearly 90 percent of people diagnosed with CLL today surviving at least five years, and most for many years longer.  

Complications of CLL or CLL Treatment

Infection

People with CLL are more likely to get infections.  

CLL Staging

Many doctors use a system called staging to help predict the likely outcome of the disease and to plan treatment for people with CLL. There are three staging systems that doctors use: the Rai staging system, the Binet staging system and the CLL International Prognostic Index (CLL-IPI). Although the Rai and Binet staging systems are still widely used, they have certain limitations in predicting which patients will have a more aggressive disease.

Immunotherapeutic Targeting of FCRL1 in CLL

Evolving insights into the B cell-restricted FCRL1 surface protein reveal that it integrates with critical signaling pathways and is a promising immunotherapeutic target in CLL. Based on preclinical evaluation of novel FCRL1 monoclonal antibodies, we propose developing chimeric antigen receptor (CAR) T cells for targeting in unique mouse models and patient-derived cells. The results will form the basis for strategic drug development and clinical testing in CLL and related B cell malignancies.
A content-looking man with long gray hair and a thick beard sits at home and looks out the window

Holding onto hope: Living with chronic lymphocytic leukemia

Table of contents:​​

CLL Society

To address the unmet needs of the CLL patient and related blood cancer communities

  • Provides disease, treatment and clinical trial information
  • Offers quarterly newsletter “The CLL Tribune”

Patients, caregivers and health professionals

Website only http://cllsociety.org/

What is CLL?

CLL Patient Databases

Maintains information on a large number of patients with chronic lymphocytic leukemia to contribute to medical research about its diagnosis, prognosis, and treatment.

  • Produces free, online reports that are statistical summaries of age, gender, geographical distribution of the incidence of CLL, morbidity, and effectiveness of treatments
  • Participation in the database is voluntary and free
  • Offers free spreadsheets allowing patients to prepare charts of their blood reports and calculation of lymphocyte doubling time.

People diagnosed with chronic lymphocytic leukemia (CLL), worldwide

303-570-3792 http://patientdatabases.org/wp/

CLL-1 CAR-T cells and trametinib for the treatment of Ras-mutated CMML and JMML

We hypothesize that demonstrating activity of CLL-1 CAR-T (CLL1CART) cell therapy with or without trametinib in pre-clinical models of chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) is the most efficient method to bring cellular therapy to patients with these orphan diseases. In Aim 1, we will determine the in vitro and vivo efficacy of CAR-T cells redirected against CLL-1 using patient-derived xenograft (PDX) models of CMML and JMML. In Aim 2, we will evaluate the role of combining trametinib with CLL1CART cells.

Clinical and molecular determinants of CLL eradication with targeted combination therapy

The genomic architecture of residual CLL and molecular determinants of disease progression after targeted combination therapy are unknown. In a phase 2 study of zanubrutinib and venetoclax in CLL, I will investigate the depth of response and genomic changes using cellular and circulating tumor DNA. Data generated from this proposal will provide foundational evidence to develop genomic markers for non-invasive monitoring of treatment response and precise prediction of outcome.

Inhibition of PKCβ as a strategy for BTK inhibitor refractory CLL

Patients with CLL that have progressed on BTK inhibitors have high risk disease with few clinical options. Here we propose a novel, selective inhibitor of PKCβ, MS-553, as a strategy for these patients. Our project will evaluate this drug alone and in combination with venetoclax preclinically and will perform correlative studies from an ongoing phase 1/2 trial of this drug alone and in combination with venetoclax.

CLL Global Research Foundation

To abolish chronic lymphocytic leukemia (CLL) as a threat to the life and health of patients.

  • Aims to fund patient-oriented projects with rapid clinical applications and to expand the knowledge of CLL on a global scale
  • Provided seed money for the formation of two CLL Research Consortiums, one in Australia and one in Israel.

Patients and health professionals interested in CLL information

Website only https://cllglobal.org/
International Resources
Canadian Resources International Resources U.S. Resources

Chronic Lymphocytic Leukemia (CLL)

BAFF-ligand CAR T-cells and pre-apheresis B cell lymphodepletion for relapsed / refractory CLL

Most CLL patients treated with CAR T-cells that target the CD19 antigen on the cell do not achieve a complete remission. CLL cells express other molecules on their surface; one of them is the receptor for BAFF (BAFF-R), which is highly expressed. We propose a phase I trial investigating LMY-920 for treatment of CLL. LMY-920 is a different type of CAR T-cell because it does not rely on an antibody structure to identify BAFF-R, but uses the structure of the ligand BAFF itself, and this may help avoid resistance to CAR T-cells.
researcher

What’s Next in Blood Cancer: Looking Ahead to 2023

The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December.

Microscopic image of leukemia cells

“Stages” of Leukemia: Understanding Classification and Progression

Table of contents

Spotlight on Chronic Lymphocytic Leukemia (CLL)

NHL & CLL Diagnosis and Treatment Update

Update On Chronic Lymphocytic Leukemia (CLL)

CLL: Navigating Treatment with BTK Inhibitors

Living With Chronic Lymphocytic Leukemia (CLL)

The Future of CLL Treatment: What’s Next?

Ofatumumab

Ofatumumab is FDA approved 

  • For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
  • For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. 
  • In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

NCI-Genetic Epidemiology Branch - Familial CLL

To study families with multiple cases of chronic lymphocytic leukemia (CLL).

  • The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is conducting a study to: find the gene or genes that cause this type of leukemia to occur in families; to describe the clinical features of familial CLL; to explore whether families prone to familial CLL are also at greater risk of other types of leukemia or cancer; to identify biomarkers or markers that predict risk in family members.
  • Participants will be asked to provide a blood sample or cells, personal and medical history, and to give consent to obtain medical records.

Families with 2 or more living individuals in the family with a history of CLL, or families in which one family member has CLL and one or more close relatives have a related blood or lymph cancer

800-518-8474 http://dceg.cancer.gov/research/clinical-studies/blood-cll-info

Evolutionary Behavior in CLL: Implications for Personalized Therapy